Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer

19961,237 citationsJournal Articlebronze Open Access

Authors

David S. Alberts · University of Arizona

P. Y. Liu · SWOG Cancer Research Network

Edward V. Hannigan · The University of Texas Medical Branch at Galveston

Robert V. O’Toole · The Ohio State University

Stephen D. Williams · Gynecologic Oncology Group

James A. Young · Eastern Cooperative Oncology Group

Ernest W. Franklin

Abstract

As compared with intravenous cisplatin, intraperitoneal cisplatin significantly improves survival and has significantly fewer toxic effects in patients with stage III ovarian cancer and residual tumor masses of 2 cm or less.

Topics & Keywords

Ovarian cancer diagnosis and treatment Intraperitoneal and Appendiceal Malignancies Testicular diseases and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 335, Issue 26, pp. 1950-1955

DOI: 10.1056/nejm199612263352603

Field-Weighted Citation Impact: 33.32